This company listing is no longer active
4KH Stock Overview
Operates as an integrated medical and cannabis company in Latin America and Europe. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Khiron Life Sciences Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.022 |
| 52 Week High | CA$0.11 |
| 52 Week Low | CA$0.016 |
| Beta | 3.14 |
| 1 Month Change | 0% |
| 3 Month Change | 1.89% |
| 1 Year Change | -75.57% |
| 3 Year Change | -92.85% |
| 5 Year Change | n/a |
| Change since IPO | -97.82% |
Recent News & Updates
Recent updates
Shareholder Returns
| 4KH | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 0% | -2.5% | -2.6% |
| 1Y | -75.6% | -15.6% | 6.9% |
Return vs Industry: 4KH underperformed the German Pharmaceuticals industry which returned -28.2% over the past year.
Return vs Market: 4KH underperformed the German Market which returned 5.9% over the past year.
Price Volatility
| 4KH volatility | |
|---|---|
| 4KH Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 5.4% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.2% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 4KH has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 4KH's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | n/a | Alvaro Torres | khiron.ca |
Khiron Life Sciences Corp. operates as an integrated medical and cannabis company in Latin America and Europe. It operates through Health Services, Medical Cannabis Products, and Wellbeing Products segments. The company focuses on the cultivation, production, distribution, and export of tetrahydrocannabinol and cannabidiol (CBD) medical cannabis.
Khiron Life Sciences Corp. Fundamentals Summary
| 4KH fundamental statistics | |
|---|---|
| Market cap | €6.31m |
| Earnings (TTM) | -€20.82m |
| Revenue (TTM) | €10.96m |
0.6x
P/S Ratio-0.3x
P/E RatioIs 4KH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4KH income statement (TTM) | |
|---|---|
| Revenue | CA$16.14m |
| Cost of Revenue | CA$9.47m |
| Gross Profit | CA$6.67m |
| Other Expenses | CA$37.33m |
| Earnings | -CA$30.66m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.13 |
| Gross Margin | 41.34% |
| Net Profit Margin | -190.00% |
| Debt/Equity Ratio | 3.0% |
How did 4KH perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/08/05 17:55 |
| End of Day Share Price | 2023/05/08 00:00 |
| Earnings | 2022/09/30 |
| Annual Earnings | 2021/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Khiron Life Sciences Corp. is covered by 4 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Kideckel | ATB Capital Markets |
| Nikolaas Faes | Bryan Garnier & Co |
| Kimberly Thompson-Hedlin | Canaccord Genuity |